MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca. [1] [2] MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion. [3]

Feb 28, 2018 · AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio.

Feb 14, 2019 · After 30 years of drug development, MedImmune will cease to exist as an industry name now that owner AstraZeneca has decided to retire the brand as part of ongoing restructuring efforts. The decision comes a little more than a month after AstraZeneca announced organizational changes meant to bolster its R&D and commercial efforts.

MedImmune’s novel ADC candidate employs the PBD payload and demonstrates early efficacy against cancer . Indication . Candidate • Novel ADC conjugated with PBD payload • Tumor regression after single dose . ADC: H1975 NSCLC xenograft: Tumor regression with single dose ADC . Best Scientific Innovation: 12 – MedImmune • Cancer stem cell ...

MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular, Renal and Metabolic Diseases, and Infection and Vaccines.

Dec 1, 2008 · MedImmune, Inc. manufactures, markets and/or distributes more than 3 drugs in the U.S.

Manufacturer: MedImmune, LLC Indications: For active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Building on our long-standing heritage in this field from Cambridge Antibody Technology (CAT) and MedImmune, we harness our extensive antibody discovery and protein engineering platform to design mAbs for therapeutic applications.

Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc. [1] as an investigational drug for the treatment of rheumatoid arthritis. Mavrilimumab has been studied in a phase 1 dose-ranging trial [2] and a phase 2a clinical trial, both sponsored by Medimmune. [3]

Mar 8, 2025 · MedImmune, the R&D arm of AstraZeneca has teamed up with California based 4DMT, a next-generation virus-based gene therapy research house developing a treatment for chronic lung disease.